They Made the Most of the...
Keeping in Mind that Immunotherapy Doesn’t...
Despite a Serious Investment in Information...
Ten Hubs Continue to Command the...
Biotechnology equipment spells big bucks for the industry’s top CEOs. [© ALYUSHIN - Fotolia.com]
Olivier A. Filliol, President and CEO
2011 Compensation: $5,379,639
2010 Compensation: $5,393,903
% Change: -0.3%
Marc N. Casper, President and CEO
2011 Compensation: $5,516,567
2010 Compensation: $2,761,689
% Change: 99.8%
Jay T. Flatley, President, CEO and Director
2011 Compensation: $9,944,147
2010 Compensation: $6,608,974
% Change: 50.5%
Edward J. Ludwig, Chairman and CEO
2011 Compensation: $10,091,273
2010 Compensation: $10,005,022
% Change: 0.9%
William P. Sullivan, President and CEO
2011 Compensation: $10,252,264
2010 Compensation: $10,442,447
% Change: -1.8%
Gregory T. Lucier, Chairman and CEO
2011 Compensation: $10,897,630
2010 Compensation: $11,498,009
% Change: -5.2%
Robert F. Friel, Chairman and CEO
2011 Compensation: $12,819,181
2010 Compensation: $7,948,297
% Change: 61.3%
Leave a comment by clicking the “Comments” icon. We want to hear your thoughts!
Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?
Be sure to add firstname.lastname@example.org
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2015 Genetic Engineering & Biotechnology News All Rights Reserved